Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization
Authors:
- Ander Estella-Hermoso de MendozaAMAnder Estella-Hermoso de Mendoza
- Marta RayoMRMarta Rayo
- Faustino MollinedoFMFaustino Mollinedo
- María J. Blanco-PrietoMaría J. Blanco-Prieto
- 1 February 2008
- journal article
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 68 (2) , 207-213
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Antitumour ether lipids: proapoptotic agents with multiple therapeutic indicationsExpert Opinion on Therapeutic Patents, 2007
- Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticlesBiomaterials, 2007
- Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid raftsBlood, 2006
- Polymorphic behaviour of Compritol®888 ATO as bulk lipid and as SLN and NLCJournal of Microencapsulation, 2006
- Activity, pharmacokinetics and tissue distribution of TLC ELL-12 (liposomal antitumor ether lipid) in rats with transplantable, s.c. methylnitrosourea-induced tumorsAnti-Cancer Drugs, 2003
- Enzymatic degradation of SLN—effect of surfactant and surfactant mixturesInternational Journal of Pharmaceutics, 1999
- Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersionsInternational Journal of Pharmaceutics, 1998
- Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanismEuropean Journal of Pharmaceutics and Biopharmaceutics, 1998
- Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parametersInternational Journal of Pharmaceutics, 1997
- Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticlesInternational Journal of Pharmaceutics, 1997